| Trial | Updated / Type |
Status | Phase | Were Results Reported |
Reported Actual Enrollment |
(MeSH) Terms |
Why Stopped
Limitations And Caveats |
Annotator decisions |
|---|---|---|---|---|---|---|---|---|
| NCT03187756 Details | 2020-03-27 Interventional | 2 | 6 | Cyclophosphamid… Hematologic Neo… Neoplasms Hematopoietic M… | Procedure has become standard of care - protocol is no longer necessary - | |||
| NCT03990974 Details | 2020-03-25 Interventional | 3 | - | Anti-Bacterial … Anti-Infective … Carcinoma Carcinoma, Hepa… Communicable Di… Infections Hepatocellular … Postoperative I… | There were difficulties in implementation - | |||
| NCT02141295 2013-005108-32 Details | 2020-03-25 Interventional | 2 | 197 | Bevacizumab Folic Acid Leucovorin Levoleucovorin Oxaliplatin Colorectal Neop… Colorectal Canc… | - - | |||
| NCT01888822 Details | 2020-03-25 Interventional | 4 | 138 | Ampicillin Ciprofloxacin Sulbactam Sultamicillin Cholecystolithi… Cholelithiasis Gallstones | - - | |||
| NCT00207831 Details | 2020-03-25 Interventional | 3 | 219 | Tegafur Adenocarcinoma Rectal Neoplasm… M0 N0-2 Rectal Cancer Stage II/III T3 or T4 (Only … | Terminated after interim analysis - | |||
| NCT04290858 Details | 2020-03-24 Interventional | 2 | 0 | Nitric Oxide COVID-19 Communicable Di… Coronavirus Inf… Dyspnea Infections Pneumonia Pneumonia, Vira… | New coordinating center has been defined (Massachusetts General Hospital) - | |||
| NCT04105374 Details | 2020-03-24 Interventional | 2/3 | 0 | Flucytosine Temozolomide Astrocytoma Glioblastoma Oligodendroglio… Anaplastic Astr… Supratentorial … | NCI approval withdrawn - | |||
| NCT01059682 Details | 2020-03-24 Interventional | 3 | 936 | Dalcetrapib Cardiovascular … Cardiovascular … | Termination of the clinical development program by the Sponsor - | |||
| NCT02999100 2016-002672-27 Details | 2020-03-23 Interventional | 1 | 31 | Oxytocin Hemorrhage Postpartum Hemo… | Inability to reliably measure plasma oxytocin levels during third stage labour, regardless of
administration method (intramuscular or inhaled). - | |||
| NCT03303794 Details | 2020-03-20 Interventional | 3 | 25 | Bupivacaine Anesthesia | Interim Analysis showed no significance - | |||
| NCT01465919 Details | 2020-03-20 Interventional | 4 | [1 Refs] | 5 | Mirtazapine Depression Depressive Diso… Hepatitis Hepatitis C | Due to the recent change in standard of care for hepatitis C. - | ||
| NCT02926638 Details | 2020-03-19 Interventional | 2/3 | 9 | Antibodies Antibodies, Mon… Antineoplastic … Erlotinib Hydro… Immunoglobulins Rilotumumab Carcinoma Lung Neoplasms MET Positive Recurrent Squam… Stage IV Squamo… | Drug company decided to terminate all sponsored clinical studies involving rilotumumab. - | |||
| NCT01673061 Details | 2020-03-19 Interventional | 4 | 21 | Epinephrine Lidocaine Norflurane Abscess | Vapocoolant not effective controlling pain compared with Lidocaine. 0 Participants analyzed. PI has left the institution. Efforts made to contact were unsuccessful. No data available | |||
| NCT04304716 Details | 2020-03-18 Interventional | 4 | 0 | Anesthetics Pain, Postopera… | Withdrawn from the IRB - | |||
| NCT03688230 2018-003439-31 Details | 2020-03-18 Interventional | 2 | 0 | Cetuximab Colorectal Neop… Metastatic Colo… | Co-development decision - | |||
| NCT03123055 2017-001292-23 Details | 2020-03-18 Interventional | 1/2 | 28 | Pembrolizumab Carcinoma Urinary Bladder… Urologic Diseas… Locally Advance… Urinary Bladder… Urological Dise… | program has been put on hold by the sponsor - | |||
| NCT01629329 Details | 2020-03-18 Interventional | 4 | 93 | Acetaminophen Aspirin Caffeine Prochlorperazin… Headache Migraine Disord… Migraine Headac… | no difference found between two groups in a preliminary analysis 0 Participants analyzed. PI has left the institution. Efforts made to contact were unsuccessful. No data available | |||
| NCT00226954 Details | 2020-03-18 Interventional | 2 | 23 | Zoledronic Acid Urologic Neopla… | - - | |||
| NCT04272775 Details | 2020-03-17 Interventional | 1 | 14 | Dexamethasone Ixazomib Lenalidomide Multiple Myelom… Neoplasms, Plas… Relapsed and/or… | Business Decision; No Safety Or Efficacy Concerns - | |||
| NCT02357147 2014-004489-85 Details | 2020-03-17 Interventional | 2 | 124 | Pemetrexed Mesothelioma Mesothelioma, M… | Due to business reasons The study was terminated due to business decision. No safety concerns involved in decision to terminate this study. |